

Active Behavior of Triple-negative Breast Cancer With Adipose Tissue Invasion: A Single Center and Retrospective Review

Junzo Yamaguchi (✉ yamaguchi.jun5@gmail.com)

fukuoka seishukai hospital <https://orcid.org/0000-0003-4434-4342>

Hiroki Moriuchi

national hospital organization,saga hospital

Takashi Ueda

fukuoka seishukai hospital

Yujo Kawashita

fukuoka seishukai hospital

Takanori Hazeyama

fukuoka seishukai hospital

Masaki Tateishi

fukuoka seishukai hospital

Shigehisa Aoki

Faculty of Medicine,saga university

Kazuyoshi Uchihashi

national hospital organization,saga hospital

Mikio Nakamura

fukuoka seishukai hospital

Research article

Keywords: Triple-negative breast cancer, Luminal breast cancer, Adipose tissue invasion, Tumor microenvironment, Patient survival

Posted Date: September 3rd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-70081/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Cancer on April 20th, 2021. See the published version at <https://doi.org/10.1186/s12885-021-08147-2>.

Abstract

Background: Interactions between adipocyte and breast cancer (BC) cells have yet to be fully elucidated. Here we investigated the prognostic impact of marginal adipose tissue invasion in both luminal breast cancer (HR+/HER2-) and triple-negative breast cancer (TNBC) (HR-/HER2-).

Methods: A total of 735 patients with early-stage invasive BC (1999-2014) were retrospectively registered. Median length of patient follow-up was 8.9 years. Survival curves were calculated using a Kaplan-Meier cumulative survival plot. The prognostic difference between two groups were assessed by the univariate Cox-proportional hazard regression model.

Results: Patients with adipose tissue invasion ($n = 614$) had a significantly poorer prognosis than those without adipose tissue invasion ($n = 121$) in overall survival (OS) (hazard ratio, 2.1; 95% Confidence interval [CI], 1.1 to 4.0; $P = 0.025$). While a poorer prognosis was observed in TNBC ($n = 137$) than in luminal BC patients ($n = 496$) (hazard ratio, 0.45; 95% CI, 0.30 to 0.68, $P < 0.001$), this aggressive nature of TNBC was noted in node-positive disease (hazard ratio, 0.3; 95% CI, 0.18 to 0.5, $P < 0.001$) but not in node-negative disease (hazard ratio, 0.78; 95% CI, 0.39 to 1.55, $P = 0.472$), and also noted in adipose tissue invasion-positive patients (hazard ratio, 0.4; 95% CI, 0.26 to 0.6, $P < 0.001$) but not in adipose tissue invasion-negative patients (hazard ratio, 0.73; 95% CI, 0.16 to 3.24, $P = 0.675$). In addition, although patients suffering from TNBC with adipose tissue invasion had a poorer outcome than those without adipose tissue invasion (hazard ratio, 3.63; 95% CI, 1.11 to 11.84; $P = 0.033$), the difference was not observed in luminal BC (hazard ratio, 1.75; 95% CI, 0.64 to 4.82; $P = 0.277$).

Conclusions: Adipose tissue invasion was correlated with poor survival in TNBC. Cancer cell invasion into local fat may be a first step on cancer progression and systemic disease in TNBC.

Background

Obesity is a risk factor for many cancers including breast cancer (BC), but little is known about the relationship between cancer-cell invasion into local fat and patient survival in BC. The tumor microenvironment is a heterogeneous population of cells consisting of the tumor cells as well as endogenous stromal cells, such as vascular endothelial cells, pericytes, fibroblasts, bone-marrow mesenchymal stromal cells, immune cells and adipocytes¹. These stromal cells are recruited by cancer cells and promote cellular migration, tumor angiogenesis, proliferation, invasion, and metastasis, as well as drug resistance². Adipocytes are especially abundant stromal partners in breast tissue³, and BC cell invasion into local fat seems to increase metastatic potential in the animal model⁴.

Triple-negative breast cancer (TNBC) accounts for roughly 10-20 %^{5,6} of all BC cases. The disease is viewed universally as the most devastating form of BC because of its aggressive nature^{7,8}. However, since there are still no markers to predict the efficacy of chemotherapy and well-defined molecular targets remain a topic of investigation⁹, current treatment options for TNBC commonly focus on cytotoxic

chemotherapy. Although more aggressive chemotherapy has resulted in an improved prognosis, it usually leads to serious deterioration in quality of life.

On the other hand, we have observed in the clinical setting that TNBC patients do not present a uniformly dismal prognosis. We have also noticed a characteristic feature of survival outcome, that is, most of the recurrent disease occurs within a few years after surgery, and the recurrence risk rapidly decreases thereafter^{6,8}. Strikingly different from luminal BC, where more than half of recurrent disease occurs more than five years after surgery^{10,11}, this finding indicates the existence of TNBC patients who have a good prognosis without systemic disease as well as those who have a poor survival with residual disease after adjuvant chemotherapy¹².

The present study aims to evaluate the significance of adipose tissue invasion on patient survival in luminal BC and TNBC. It is very important to explore the role of adipose tissue for cancer progression.

Methods

Patients

This retrospective study was approved by our institutional review board. We reviewed records from all patients with primary invasive carcinoma of the breast who underwent surgery between 1999 and 2014 at our institution (National Hospital Organization, Saga Hospital). Of the 858 patients, 123 were excluded for the following reasons: synchronous bilateral breast cancer ($N = 28$), metachronous bilateral breast cancer in the period ($N = 9$), clinically multifocal or multicentric cancers in the unilateral breast ($N = 39$), distant metastasis ($N = 24$), inflammatory carcinoma of the breast ($N = 6$), ipsilateral breast recurrence after breast-conserving surgery ($N = 2$), tissues inappropriate for histological review due to preoperative neoadjuvant chemotherapy ($N = 4$), and patients who died within one year ($N = 11$). Thus, our final study population comprised 86% (735/858) of the total potential patients. All were women except one case. The patients were followed up until June 31, 2019, the median length of follow-up being 107 months (8.9 years) (range, 1-244 months) after surgery. Of the 735 patients in the current study, 472 (64%) had been included in our previous reports¹³. This study did not involve the use of personal identifying information and individuals or families in the case of the deceased are not identified from data because of consecutive numbers of patients.

Survival analysis

The events used to determine the breast cancer-specific survival (BCSS) rate included death due to breast cancer. The overall survival (OS) rate included death due to breast cancer and other causes. The survival of the two groups in each analysis was compared in the entire group of patients and subgroups adjusted for clinical-pathological factors.

Tissue preparation and histological analyses

The resected breast and lymph node tissues were fixed in 10% formalin and the breast tissues were cut into 5-mm-thick slices^{13,14}. Each paraffin-embedded block was cut into 4- μ m-thick sections and stained with hematoxylin and eosin. For the histological review, information on pathological tumor size, lymph node involvement (pN0: no regional lymph node metastasis, pN1: metastasis in 1 to 3 axillary ipsilateral lymph node, pN2: metastasis in 4-9 ipsilateral axillary lymph node, pN3: metastasis in 10 or more ipsilateral axillary lymph node), lymphatic vessel invasion, histological grade, adipose tissue invasion, hormone receptors (HR) status, and human epidermal growth factor receptor 2 (HER2) status was obtained from the prospective reports by pathologists (SA and KU, with 19 and 15 years of experience, respectively). The histological parameters between 1999 and 2009 were obtained from retrospective reviews conducted during the previous study by pathologists blinded to the survival outcome¹³.

Definitions of adipose tissue and marginal adipose tissue invasion

Histological sections were obtained from the whole cut surface of the tumor at the maximal diameter. The definition of adipose tissue and marginal adipose tissue invasion followed that in our previous reports^{13,14}. Adipose tissue was defined as a pure aggregate consisting of more than 20 fat cells without intervening fibrous tissues in the breast. The adipose tissue included tissues surrounding the mammary ducts or lobules, as well as those in the subcutaneous layers. Furthermore, fibrous tissue and fibroadipose tissue (fat cells mixed with various fibrous tissues) around the terminal duct-lobular unit were strictly differentiated from adipose tissues. Marginal adipose tissue invasion was defined as either the presence of more than 20 cancer cells in direct contact with the adipose tissue or as the presence of cancer cells in the adipose tissue. Pathologists reviewing breast cancers have routinely reported on the presence or absence of adipose tissue invasion in their clinical reports since 1999 (1999-2014). Representative images of negative and positive adipose tissue invasion are shown in Figure 1a and b, respectively.

Hormone receptor and HER2 status

Hormone receptor and HER2 status were evaluated as described previously¹³⁻¹⁵. Cases positive for estrogen receptor (ER) and progesterone receptor were defined as those with more than 10% of the cancer cell nuclei stained (ER-rich tumor). HER2 expression status was obtained on the basis of immunohistochemical analysis using commercially available antibodies. The intensity of HER2 staining was scored as follows: 0, 1+, 2+, or 3+. In the summary of results, we classified scores of 0 and 1+ as HER2 negative and scores of 3+ as HER2 positive. A HER2 score of 2+ was regarded as HER2-borderline and assessed by means of FISH assay.

Statistical analysis

Univariate analysis was carried out by Student *t* test, and χ^2 analysis. The prognostic difference between two groups (adipose tissue invasion-negative patients vs. adipose tissue invasion-positive patients and luminal BC vs. TNBC) were assessed by the univariate Cox-proportional hazard regression model.

Survival curves were calculated using a Kaplan-Meier cumulative survival plot. Statistical analysis was conducted using the software StatView 5.0 for Mac (SAS Institute, Cary, NC). $P < 0.05$ was considered to indicate a statistically significant difference.

Results

Clinical-pathologic parameters for patients with and without adipose tissue invasion, and prognostic outcome (BCSS, OS)

Of the 735 cases, 614 (84%) and 121 (16%) were patients with and without adipose tissue invasion, respectively. We compared the two groups (Table 1). Patient age and body mass index were similar in the two groups. Tumor size was significantly larger and the frequency of nodal involvement significantly higher in patients with adipose tissue invasion ($P < 0.001$ in both). Stage I (pathological classification) was observed much more frequently in patients without adipose tissue invasion, while stage II or III was observed much more frequently in patients with adipose tissue invasion. ($P < 0.001$). The frequency of lymphatic vessel invasion was significantly higher in patients with adipose tissue invasion ($P < 0.001$). On the other hand, a low histological grade (grade I and II) was observed much more frequently in patients with adipose tissue invasion, and a high histological grade (grade III) was observed much more frequently in patients without adipose tissue invasion ($P = 0.019$).

We compared survival outcome between the two groups. The results of overall analysis (all) and subgroup analysis are shown in Table 2. A poorer prognosis was observed among patients with adipose tissue invasion (N = 609) than among those without adipose tissue invasion (N = 119) in breast cancer-specific survival (BCSS) (hazard ratio, 3.23; 95% confidence interval [CI], 1.31 to 7.95; $P = 0.010$) and overall survival (OS) (hazard ratio, 2.1; 95% CI, 1.1 to 4.0; $P = 0.025$) in the entire group of patients (all). Then, we adjusted for age (< 70 and ≥ 70), pathological stage (I, II, III), and histologic grade (low grade and high grade) in OS. Patients with adipose tissue invasion showed a poorer rate of survival than those without adipose tissue invasion in the age of < 70 (hazard ratio, 2.69; 95% CI, 1.09 to 6.65; $P = 0.032$) and histologic high grade tumors (hazard ratio, 3.5; 95% CI, 1.27 to 9.67; $P = 0.016$).

Clinical-pathologic parameters and treatment in luminal BC and TNBC

Of the 735 cases, 502 (68%) were luminal BC (estrogen and progesterone receptors positive/human epidermal growth factor receptor type 2 negative; HR+/HER2-), 137 (19%) were TNBC (HR-/HER2-) and 59 (8%) were HER2-enriched BC (HR-/HER2+). The remaining 37 cases consisted of 29 HR+/HER2+ breast cancers (4%) and 8 unknown cases. Since the number of HER2-enriched BC cases was small and adjuvant one-year treatment with trastuzumab had been administered since 2009 (1999-2014), we compared the two tumor subtypes in this study, that is luminal BC and TNBC.

First, we compared clinical-pathological parameters between the two subtypes (Table 3). No difference was observed in either patient age ($P = 0.429$) or body mass index ($P = 0.233$). A statistically significant difference was observed in the pathologic tumor size ($P = 0.008$), but the frequency of lymph node

involvement, stage and lymphatic vessel invasion was similar ($P = 0.832$, $P = 0.403$ and $P = 0.259$, respectively). Luminal BC was associated with a lower histological grade, while TNBC were associated with a higher histological grade ($P < 0.001$). With regard to adipose tissue invasion, the frequency of masses with adipose tissue invasion was higher in luminal BC cases, while the frequency of masses without adipose tissue invasion was higher in TNBC cases ($P < 0.001$).

Furthermore, we outlined the treatment administered for luminal BC and TNBC patients (Continued). No difference was observed among cases undergoing breast surgery, but the frequency of axillary lymph node dissection (ALND) was higher in TNBC patients ($P = 0.002$). Endocrine therapy was performed for 97% of luminal BC patients and for 23% of TNBC patients ($P < 0.001$). Endocrine therapy was indicated for tumors in which more than 1% of the cancer cell nuclei were stained. On the other hand, intravenous routine adjuvant chemotherapy (doxorubicin-cyclophosphamide, docetaxel-cyclophosphamide, epirubicin-cyclophosphamide, epirubicin-cyclophosphamide followed by paclitaxel, fluorouracil-epirubicin-cyclophosphamide followed by docetaxel, fluorouracil-doxorubicin-cyclophosphamide, docetaxel followed by epirubicin-cyclophosphamide) (ASCO Clinical Practice Guideline 2018¹⁶) was selected for 43% of luminal BC patients and for 75% of TNBC patients ($P < 0.001$). The median cycle of intravenous chemotherapy was four in luminal BC and six in TNBC. We usually establish the chemotherapy regimen (including no treatment) on the basis of the attending physician's judgment, with reference to tumor size, lymph node status, overall performance status, presence or absence of medical comorbidities, and patient age. With regard to radiation therapy, no difference was observed between the two groups.

Comparison of survival outcome (OS) between luminal BC and TNBC

Next, we compared survival outcome between the two groups. The results of overall analysis and subgroup analysis are shown in Table 4. A poorer prognosis was observed among TNBC patients ($n = 137$) than among luminal BC patients ($n = 496$) in OS (hazard ratio, 0.45; 95% CI, 0.30 to 0.68, $P < 0.001$) in the entire group of patients (all). In subgroup analyses, a significantly poor outcome of TNBC was observed in the age (< 70 and ≥ 70) ($P = 0.006$ and $P = 0.001$, respectively), tumor size (≤ 2 cm and > 2 cm) ($P = 0.005$ and $P = 0.016$, respectively). On the other hand, no difference was observed in node-negative disease (hazard ratio, 0.78; 95% CI, 0.39 to 1.55, $P = 0.472$) (luminal BC and TNBC were 314 and 84 cases, respectively), but a marked difference was observed in node-positive disease (hazard ratio, 0.3; 95% CI, 0.18 to 0.5, $P < 0.001$) (176 and 45 cases, respectively) (also shown in Figure 2a and b). With regard to stage, no difference was seen in stage I, but a significant difference was noted in stage II ($P = 0.002$) and III ($P = 0.012$). In addition, a poorer prognosis was observed among TNBC patients than among luminal BC patients in histologic low grade tumors (hazard ratio, 0.32; 95% CI, 0.18 to 0.59, $P < 0.001$), but the prognosis was similar in high grade tumors ($P = 0.23$). Moreover, although no difference was observed in adipose tissue invasion-negative patients (hazard ratio, 0.73; 95% CI, 0.16 to 3.24, $P = 0.675$) (luminal BC and TNBC were 54 and 35 cases, respectively), there was a remarkable difference in adipose tissue invasion-positive patients (hazard ratio, 0.4; 95% CI, 0.26 to 0.6, $P < 0.001$) (those were 442 and 102 cases, respectively) (Figure 2c and d).

Prognostic outcome for patients with and without adipose tissue invasion in luminal BC and TNBCsubtypes

We determined the prognosis of patients with and without adipose tissue invasion in the tumor subtypes. As shown in Table 5, no difference was observed in BCSS (hazard ratio, 1.75; 95% CI, 0.55 to 5.63; $P = 0.346$) or OS (hazard ratio, 1.75; 95% CI, 0.64 to 4.82; $P = 0.277$) when compared the cases of luminal BC with and without adipose tissue invasion (adipose tissue invasion-negative and adipose tissue invasion-positive cases were 54 and 442, respectively). On the other hand, we compared cases of TNBC with and without adipose tissue invasion. A significant differences was observed between the two groups in both BCSS (hazard ratio, 8.63; 95% CI, 1.17 to 63.66; $P = 0.035$) and OS (hazard ratio, 3.63; 95% CI, 1.11 to 11.84; $P = 0.033$) (those were 35 and 102, respectively). In TNBC, one of the patients without adipose tissue invasion died due to breast cancer diagnosed as node-positive disease at surgery.

Discussion

Our study design focused on two tumor subtypes of BC (HR+/HER2- and HR-/HER2-) and defined cases with ER-rich tumors (more than 10% of the cancer cell nuclei stained) as hormone receptor-positive carcinoma. Furthermore, although this study is a single center review, we have made a sharp distinction between adipose tissue invasion-negative and adipose tissue invasion-positive BC. As a result, we obtained three valuable findings. First, tumors with adipose tissue invasion had a poorer prognosis than those without adipose tissue invasion in OS, as observed in high grade tumors. Second, although, as might be anticipated, TNBC showed a poorer survival than luminal BC, it was remarkable to find this to be the case in node-positive disease as well as adipose tissue invasion-positive patients. Third, patients suffering from TNBC with adipose tissue invasion had a poorer outcome than those without adipose tissue invasion, in contrast to luminal BC cases. Namely, it is likely that a poorer outcome of tumors with adipose tissue invasion was due to the cases of TNBC.

We reported previously that patients with adipose tissue invasion showed a poorer disease-free survival (DFS) than those without adipose tissue invasion^{13,14}. In the present study, the poor outcome was observed both in breast cancer-specific survival (BCSS) and, importantly, in OS. In addition, the results were found in TNBC patients. Marginal adipose tissue invasion resulted in marked cell changes in the course of tumor activity in TNBC. When we compared TNBC to luminal BC, we found that the poor survival of TNBC was seen in node-positive disease but not in node-negative disease and, therefore, that the highly aggressive nature of TNBC was due to lymph-node metastasis but not due to the tumor size or histological tumor grade in this study. Since adipose tissue invasion independently affected the nodal involvement in our previous study¹⁴, it is suggested that the active behavior of adipose tissue invasion-positive TNBC is related to lymph-node metastasis.

Currently, the literature is scattered with studies on adipocyte biology in BC^{1,3}. Indeed, adipocytes are considered to constitute a critical cell type in the tumor microenvironment of BC^{17,18}. Recently, moreover, some investigators highlighted the striking effects of adipocytes on the human TNBC cell line, that is,

enhanced cell migration and invasion¹⁹. In the present study, it is suggested that nodal status is a very strong prognostic factor in TNBC. A relationship may exist between marginal adipose tissue invasion and the involvement of the functional lymphatic endothelium.

Meanwhile, a thoroughgoing estimation of a patient's prognosis is crucial to avoid overtreatment and that biological understanding helps us to escalate and de-escalate therapy even in high risk tumors²⁰. In TNBC, few patients suffer recurrence between 5 and 10 years after surgery, and it is unlikely that chemotherapy exerts any major impact on late recurrence²¹. We think that there is a group of patients whose disease is localized at the time of diagnosis. As shown in the results, of TNBC without adipose tissue invasion (n = 35) BC related-death was only one case. Although the confidence interval was very broad and the risk was unstable, most of adipose tissue invasion-negative TNBC seem to be localized disease. With regard to adjuvant management strategies, it is conceivable that the absolute benefit of chemotherapy is relatively small in those cases.

Tumors are composed of both cancer stem-like cells and other differentiated cancer cells²². It has been proposed that the cancer stem-cell theory provides an insight into the aggressive nature of TNBC¹². The TNBC phenotypes are highly similar to the cancer stem-cell phenotypes responsible for cancer progression, lymph node metastasis and distant metastasis as well as tumor initiation^{12,23}. In addition, accumulating evidence indicates that epithelial to mesenchymal transition shows similarities between the TNBC and cancer stem-cell phenotypes. It was reported that adipocytes from visceral white adipose tissue exert an enhanced effect on the epithelial to mesenchymal transition of BC cells²⁴. There may be some relationship between cancer cell invasion into adipose tissue and expanding breast cancer stem cells in TNBC. Chemotherapy can eliminate the bulk of differentiated cancer cells but fail to eliminate breast cancer stem cells²⁵.

The present study is limited in that it is an observational retrospective study, and it is relatively small in scale for an analysis of prognosis. Moreover, tumor infiltrating lymphocytes (TILs) have been shown to exhibit a good prognosis in histologic screening, particularly in TNBC²⁶. This might be useful for clinical decisions as a prognostic marker and should be included in pathology reports, but we have no data on the assessment of TILs.

Conclusion

In conclusion, cancer-cell invasion into local fat seems to change a tumor from "a silent bystander to an active facilitator¹⁷" in TNBC. The next question is: Does adipose tissue invasion signal the start of the acquirement of malignant properties or the start of systemic disease in TNBC tumor cells?

Abbreviations

BC: Breast cancer, BCSS: breast cancer-specific survival, CI; Confidence interval, ER: estrogen receptor, HR: hormone receptors, HER2: human epidermal growth factor receptor 2, OS: overall survival, TNBC : triple-

negative breast cancer,

Declarations

Ethics approval and consent to participate

This retrospective study was approved by our institutional review board, and the requirement to obtain informed consent was waived for the retrospective study.

Consent for publication

Not applicable.

Availability of data and materials

All data (except for treatment data) generated or analysed for the current study are included in this supplementary information files. Treatment datasets will be available from the corresponding author on reasonable request.

Competing interests and Funding

The authors have declared no conflicts of interest.

There are none regarding funding.

Authors' contributions

JY and HM conceived the study design and analytical concept, and JY was a major contributor in writing the manuscript and critical revision of the manuscript. JY and YK performed statistical analyses and drafted the manuscript. HM, TU, YK, TH, and MT contributed to the acquisition of clinical patient informations. SA and KU contributed to the acquisition of pathology data. MN helped with data management and supported our work. All authors read and approved the final manuscript.

Acknowledgement

We thank all the patients and associates who participated in this study.

References

1. Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. [Tumor-associated stromal cells as key contributors to the tumor microenvironment](#). Breast Cancer Res. 2016 Aug 11;18(1):84. doi: 10.1186/s13058-016-0740-2. PMID: 27515302
2. Hanahan D, Coussens LM: Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer cell 2012 Mar 20;21(3):309-22. doi: 10.1016/j.ccr.2012.02.022.

PMID: 22439926

3. Huang CK, Chang PH, Kuo WH, Chen CL, Jeng YM, Chang KJ, Shew JY, Hu CM, Lee WH. Adipocytes promote malignant growth of breast tumours with monocarboxylate transporter 2 expression via β -hydroxybutyrate. *Nat Commun*. 2017 Mar 10;8:14706. doi: 10.1038/ncomms14706. PMID: 28281525
4. Picon-Ruiz M, Pan C, Drews-Elger K, Jang K, Besser AH, Zhao D, Morata-Tarifa C, Kim M, Ince TA, Azzam DJ, Wander SA, Wang B, Ergonul B, Datar RH, Cote RJ, Howard GA, El-Ashry D, Torné-Poyatos P, Marchal JA, Slingerland JM. [Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression](#). *Cancer Res*. 2016 Jan 15;76(2):491-504. doi: 10.1158/0008-5472.CAN-15-0927. Epub 2016 Jan 7. PMID: 26744520
5. Saraiva DP, Guadalupe Cabral M, Jacinto A, Braga S. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. *ESMO Open*. 2017 Sep 14;2(4):e000208. doi: 10.1136/esmoopen-2017-000208. eCollection 2017. PMID: 29018573
6. [Kumar P, Aggarwal R](#). An overview of triple-negative breast cancer. *Arch Gynecol Obstet*. 2016 Feb;293(2):247-69. doi: 10.1007/s00404-015-3859-y. Epub 2015 Sep 4. PMID: 26341644
7. Foulkes WD, Smith IE, Reis-Filho JS. [Triple-negative breast cancer](#). *N Engl J Med*. 2010 Nov 11;363(20):1938-48. doi: 10.1056/NEJMra1001389. PMID: 21067385
8. Kast K, Link T, Friedrich K, Petzold A, Niedostatek A, Schoffer O, Werner C, Klug SJ, Werner A, Gatzweiler A, Richter B, Baretton G, Wimberger P. Impact of breast cancer subtypes and patterns of metastasis on outcome. *Breast Cancer Res Treat*. 2015 Apr;150(3):621-9. doi: 10.1007/s10549-015-3341-3. Epub 2015 Mar 18. PMID: 25783184
9. Xiao M, Lou C, Xiao H, Yang Y, Cai X, Li C, Jia S, Huang Y. [MiR-128 regulation of glucose metabolism and cell proliferation in triple-negative breast cancer](#). *Br J Surg*. 2018 Jan;105(1):75-85. doi: 10.1002/bjs.10646. Epub 2017 Nov 8. PMID: 29116653
10. Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. *Lancet Oncol*. 2013 Oct;14(11):1067-1076. doi: 10.1016/S1470-2045(13)70387-5. Epub 2013 Sep 12. PMID: 24035531
11. Dubsy P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrman MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group (ABCSSG). The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. *Br J Cancer*. 2013 Dec 10;109(12):2959-64. doi: 10.1038/bjc.2013.671. Epub 2013 Oct 24. PMID: 24157828
12. [Park SY, Choi JH, Nam JS](#): Targeting Cancer Stem Cells in Triple-Negative Breast Cancer. *Cancers (Basel)*. 2019 Jul 9;11(7):965. doi: 10.3390/cancers11070965. PMID: 31324052

13. Moriuchi H, Yamaguchi J, Hayashi H, Ohtani H, Shimokawa I, Abiru H, Okada H, Eguchi S. [Cancer Cell Interaction with Adipose Tissue: Correlation with the Finding of Spiculation at Mammography](#). *Radiology*. 2016 Apr;279(1):56-64. doi: 10.1148/radiol.2015142191. Epub 2015 Oct 9. PMID: 26458207
14. Yamaguchi J, Ohtani H, Nakamura K, Shimokawa I, Kanematsu T. Prognostic impact of marginal adipose tissue invasion in ductal carcinoma of the breast. *Am J Clin Pathol*. 2008 Sep;130(3):382-8. doi: 10.1309/MX6KKA1UNJ1YG8VN. PMID: 18701411
15. Kuba S, Ohtani H, Yamaguchi J, Hayashi H, Uga T, Kanematsu T, Shimokawa I. Incomplete inside-out growth pattern in invasive breast carcinoma: association with lymph vessel invasion and recurrence-free survival. *Virchows Arch*. 2011 Feb;458(2):159-69. doi: 10.1007/s00428-010-1033-2. Epub 2011 Jan 8. PMID: 21221635
16. Denduluri N, Chavez-MacGregor M, Telli ML, Eisen A, Graff SL, Hassett MJ, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Somerfield MR, Trudeau ME, Wolff AC, Giordano SH. J. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. *Clin Oncol*. 2018 Aug 10;36(23):2433-2443. doi: 10.1200/JCO.2018.78.8604. Epub 2018 May 22. PMID: 29787356
17. [Choi J, Cha YJ, Koo JS](#): Adipocyte biology in breast cancer: From silent bystander to active facilitator. *Prog Lipid Res*. 2018 Jan;69:11-20. doi: 10.1016/j.plipres.2017.11.002. Epub 2017 Nov 21. PMID: 29175445
18. Pallegar NK, Christian SL. Adipocytes in the Tumour Microenvironment. *Adv Exp Med Biol*. 2020;1234:1-13. doi: 10.1007/978-3-030-37184-5_1. PMID: 32040851
19. Nickel A, Blücher C, Kadri OA, Schwagarus N, Müller S, Schaab M, Thiery J, Burkhardt R, Stadler SC. Adipocytes induce distinct gene expression profiles in mammary tumor cells and enhance inflammatory signaling in invasive breast cancer cells. *Sci Rep*. 2018 Jun 21;8(1):9482. doi: 10.1038/s41598-018-27210-w. PMID: 29930291
20. [Morigi C](#). Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer. 2017 Apr 7;11:732. doi: 10.3332/ecancer.2017.732. eCollection 2017. PMID: 28491135
21. Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. *J Clin Oncol*. 2014 Jul 10;32(20):2142-50. doi: 10.1200/JCO.2013.53.1608. Epub 2014 Jun 2. PMID: 24888816
22. Kreso A, Dick JE. Evolution of the cancer stem cell model. *Cell Stem Cell*. 2014 Mar 6;14(3):275-91. doi: 10.1016/j.stem.2014.02.006. PMID: 24607403
23. Lee KL, Kuo YC, Ho YS, Huang YH. [Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness](#). *Cancers*. 2019 Sep 9;11(9):1334. doi: 10.3390/cancers11091334. PMID: 31505803

24. Ritter A, Friemel A, Fornoff F, Adjan M, Solbach C, Yuan J, Louwen F. Characterization of adipose-derived stem cells from subcutaneous and visceral adipose tissues and their function in breast cancer cells. 2015 Oct 27;6(33):34475-93. doi: 10.18632/oncotarget.5922. PMID: 26439686
25. Tominaga K, Minato H, Murayama T, Sasahara A, Nishimura T, Kiyokawa E, Kanauchi H, Shimizu S, Sato A, Nishioka K, Tsuji EI, Yano M, Ogawa T, Ishii H, Mori M, Akashi K, Okamoto K, Tanabe M, Tada KI, Tojo A, Gotoh N. Semaphorin signaling via MICAL3 induces symmetric cell division to expand breast cancer stem-like cells. Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):625-630. doi: 10.1073/pnas.1806851116. Epub 2018 Dec 26. PMID: 30587593
26. Salgado R, Loi S. Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance. Lancet Oncol. 2018 Jan;19(1):3-5. doi: 10.1016/S1470-2045(17)30905-1. Epub 2017 Dec 7. PMID: 29233560

Tables

Table 1. Comparison of patients with and patients without adipose tissue invasion (n = 735)				
	ATI-negative	ATI-positive		
Clinical-Pathologic Features	(N = 121) #1 #2	(N = 614) #1 #3	P Value	χ^2 #4
age (y) #5	58.0 ± 13.8 (26-86)	58.2 ± 13.1 (27-99)	0.872	...
Body mass index (kg/m ²) #5	22.8 ± 4.3 (13.6-37.7)	23.4 ± 3.8 (14.2-39.7)	0.105	...
Tumor size (cm) #5	0.9 ± 0.7 (0.04-4.4)	2.1 ± 1.5 (0.1-13)	< 0.001	...
Lymph node involvement				
Negative	103 (89)	357 (59)	< 0.001	37.0 (1)
Positive	13 (11)	246 (41)		
Stage (pathological)				
I	97 (85)	265 (45)	< 0.001	63.6 (2)
II	14 (12)	220 (37)		
III	3 (3)	110 (18)		
Lymphatic vessel invasion				
Negative	108 (89)	385 (64)	< 0.001	29.3 (1)
Positive	13 (11)	215 (36)		
Histologic grade				
I, II (low)	64 (53)	388 (64)	0.019	5.5 (1)
III (high)	57 (47)	216 (36)		
Note. ATI = adipose tissue invasion				
The t-statistics for age, body mass index, and tumor size, respectively, were as follows; 0.16 (df, 733), 1.62 (df, 709), 8.6 (df, 724),				
The 95% confidence intervals for age, body mass index, and tumor size were as follows: -2.37, 2.79; -0.13, 1.4; 0.91, 1.45.				
#1 Except where indicated, data are number of patients, with percentage in parentheses				
#2 Data are missing from five patients for lymph node involvement and seven patients for stage.				
#3 Data are missing from 11 patients for lymph node involvement, 19 patients for stage, 14 patients for lymphatic vessel invasion, and 10 patients for histologic grade.				
#4 Numbers in parentheses are the <i>df</i> .				
#5 Data are means ± standard deviations, with range in parentheses.				

Table 2. Comparison of survival (BCSS, OS) in patients with and patients without adipose tissue invasion.					
Survival	Patient Groups	ATI-negative	ATI-positive	Hazard Ratio (95% CI)	P Value
		No of Events/No of Patients (%)	No of Events/No of Patients (%)		
BCSS	All	5/119 (4)	89/609 (15)	3.23 (1.31-7.95)	0.01
OS	All	10/119 (8)	114/609 (19)	2.1 (1.1-4.0)	0.025
	Age				
	< 70	5/91 (5)	77/476 (16)	2.69 (1.09-6.65)	0.032
	>= 70	5/28 (18)	37/133 (28)	1.58 (0.62-4.04)	0.337
	Lymph node involvement				
	Negative	8/101 (8)	41/355 (12)	1.37 (0.64-2.91)	0.423
	Positive	1/13 (8)	71/243 (29)	3.66 (0.51-26.34)	0.198
	Stage				
	I	8/95 (8)	25/265 (9)	1.07 (0.48-2.37)	0.874
	II	1/14 (7)	36/217 (17)	1.61 (0.22-11.78)	0.64
	III	0/3 (0)	49/108 (45)	-	-
	Histologic grade				
	I, II	6/62 (10)	58/387 (15)	1.45 (0.62-3.36)	0.39
	III	4/57 (7)	54/212 (25)	3.5 (1.27-9.67)	0.016

Note. BCSS = breast cancer-specific survival, OS = overall survival

Table 3. Clinical-pathologic parameters in luminalBC and TNBC, and treatment in those

	Luminal BC (N = 502) ^{#1 #2}	TNBC (N = 137) ^{#1 #3}	P Value	χ^2 ^{#4}
Clinical-Pathologic Features				
Age (y) ^{#5}	58.4 ± 13.4 (29-99)	59.4 ± 13.0 (26-89)	0.429	...
Body mass index (kg/m ²) ^{#5}	23.3 ± 3.9 (14.2-39.7)	22.9 ± 3.9 (13.6-37.8)	0.233	...
Tumor size (cm) ^{#5}	1.9 ± 1.3 (0.04-10)	2.2 ± 1.9 (0.1-13)	0.008	...
Lymph node involvement				
Negative	318 (64)	84 (65)	0.832	0.05 (1)
Positive	178 (36)	45 (35)		
Stage (pathological)				
I	259 (53)	61 (48)	0.403	1.82 (2)
II	164 (33)	43 (34)		
III	67 (14)	23 (18)		
Lymphatic vessel invasion				
Negative	336 (68)	96 (73)	0.259	1.27 (1)
Positive	161 (32)	36 (27)		
Histologic grade				
I II	378 (76)	48 (36)	< 0.001	76.53 (1)
III	121 (24)	86 (64)		
Adipose tissue invasion				
Negative	56 (11)	35 (26)	< 0.001	18.25 (1)
Positive	446 (89)	102 (74)		
Treatment				
Surgery for breast				
Bt	285 (57)	78 (57)	0.973	0.001 (1)
Bp	217 (43)	59 (43)		
Surgery for axillary lymph node				
ALND	229 (46)	76 (55)	0.002	15.05 (3)
sampling procedure	189 (38)	33 (24)		
SNB ^{#6}	79 (16)	22 (16)		
nil	5 (1)	6 (4)		
Endocrine therapy	487 (97)	32 (23)	< 0.001	382.80 (1)
Chemotherapy				
intravenous	218 (43)	103 (75)	< 0.001	56.69 (2)
oral only ^{#7}	19 (4)	11 (8)		
nil	265 (53)	23 (17)		
Radiation therapy				
PMRT	23 (5)	6 (4)	0.902	0.21 (2)
post conservative surgery	182 (36)	47 (34)		
nil	297 (59)	84 (61)		

Note. Luminal BC = luminal breast cancer, TNBC = triple-negative breast cancer

The t-statistics for age, body mass index, and tumor size, respectively, were as follows: -0.79 (df, 637), 1.19 (df, 619), -2.67 (df, 630)

#1 Except where indicated, data are number of patients, with percentage in parentheses

#2 Data are missing from six patients for lymph node involvement, 12 patients for stage, five patients for lymphatic vessel invasion, and three patients for histologic grade.

#3 Data are missing from eight patients for lymph node involvement, 10 patients for stage, five patients for lymphatic vessel invasion, and three patients for histologic grade.

#4 Numbers in parentheses are the df.

#5 Data are means ± standard deviations, with range in parentheses.

Treatment

Note. ALND = axillary lymph node dissection, SNB = sentinel node biopsy, PMRT: postmastectomy radiation therapy

#6 SNB had been conducted since 2010 (1999-2014).


#7 Oral uracil and tegafur were selected.

Patient Groups	Luminal BC	TNBC	Hazard Ratio (95%CI)	P Value
	No of Events/No of Patients (%)	No of Events/No of Patients (%)		
All	66/496 (13)	36/137 (26)	0.45 (0.3-0.68)	< 0.001
Age				
< 70	41/380 (11)	22/106 (21)	0.48 (0.29-0.81)	0.006
>= 70	25/116 (22)	14/31 (45)	0.34 (0.17-0.65)	0.001
Tumor size (cm)				
<= 2	36/346 (10)	18/84 (21)	0.44 (0.25-0.78)	0.005
> 2	30/146 (21)	18/50 (36)	0.49 (0.27-0.87)	0.016
Lymph node involvement #1				
Negative	31/314 (10)	11/84 (13)	0.78 (0.39-1.55)	0.472
Positive	35/176 (20)	23/45 (51)	0.3 (0.18-0.5)	< 0.001
Stage				
I	22/257 (9)	7/61 (11)	0.78 (0.33-1.82)	0.563
II	18/161 (11)	13/43 (30)	0.32 (0.16-0.65)	0.002
III	24/66 (36)	14/23 (61)	0.43 (0.22-0.83)	0.012
Histologic grade				
I, II	44/375 (12)	14/48 (29)	0.32 (0.18-0.59)	< 0.001
III	22/118 (19)	22/86 (26)	0.7 (0.39-1.26)	0.23
Adipose tissue invasion #2				
Negative	4/54 (7)	3/35 (9)	0.73 (0.16-3.24)	0.675
Positive	62/442 (14)	33/102 (32)	0.4 (0.26-0.6)	< 0.001
#1 Refer to Figure 2a and b.				
#2 Refer to Figure 2c and d.				

Subtype	Survival	ATI-negative	ATI-positive	Hazard Ratio (95%CI)	P Value
		No of Events/No of Patients (%)	No of Events/No of Patients (%)		
Luminal BC	BCSS	3/54 (6)	47/442 (11)	1.75 (0.55-5.63)	0.346
	OS	4/54 (7) #1	62/442 (14) #1	1.75 (0.64-4.82)	0.277
TNBC	BCSS	1/35 (3)	26/102 (25)	8.63 (1.17-63.66)	0.035
	OS	3/35 (9) #1	33/102 (32) #1	3.63 (1.11-11.84)	0.033
#1 Data were also shown in Table 4.					
Note. BCSS = breast cancer-specific survival, OS = overall survival					

Figures

a. ATI-negative



b. ATI-positive




Figure 1

Histologic examination. Images show, a, cancer cells adjacent to a fibrous stroma devoid of adipocytes (adipose tissue invasion <ATI>-negative), and, b, cancer cells infiltrating directly into the surrounding adipose tissue (ATI-positive).

FIGURE 2

J Yamaguchi.

a. Node-negative disease




FIGURE 2

J Yamaguchi.

b. Node-positive disease




FIGURE 2

J Yamaguchi.

c. ATI-negative patients




FIGURE 2

J Yamaguchi.

d. ATI-positive patients




Figure 2

Comparison of survival outcome (OS) between luminal BC and TNBC in nodal status (a, b) and adipose tissue invasion (ATI) status (c, d). Graphs show, the Kaplan-Meier Plot of survival in node-negative disease (a), node-positive disease (b), ATI-negative patients (c), and ATI-positive patients (d). a $P = 0.472$, b $P < 0.001$, c $P = 0.675$, d $P < 0.001$.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [19992014.735casesavailabilityofdata.xls](#)